Viatris

Viatris to Participate in the BofA Securities 2024 Health Care Conference

Retrieved on: 
Thursday, May 2, 2024
Bank of America, BofA Securities, Encore, Conference, Viatris, Interest

PITTSBURGH, May 2, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the BofA Securities 2024 Health Care Conference at the Encore Hotel in Las Vegas, Nevada on Tuesday, May 14, 2024.

Key Points: 
  • PITTSBURGH, May 2, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the BofA Securities 2024 Health Care Conference at the Encore Hotel in Las Vegas, Nevada on Tuesday, May 14, 2024.
  • Chief Financial Officer Doretta Mistras and Chief R&D Officer Philippe Martin will represent the company in a fireside chat scheduled at 10 a.m. PT / 1 p.m.
  • Interested parties can access a live webcast of the event at investor.viatris.com .
  • An archived version also will be available following the live event and can be accessed at the same location for a limited time.

First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

Retrieved on: 
Thursday, April 11, 2024
PS, FDA, Ciliary muscle, Patient, IOL, SPA, Food, DSM-IV codes, OCUP, RK, Viatris, Aberration, Protocol, GLARE, Keratoconus, SMILE, Ophthalmology, Pupil, Visual acuity, Pharmaceutical industry

FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the enrollment of the first subject in the LYNX-2 Phase 3 registration study evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the treatment of decreased visual acuity under low (mesopic) light conditions following keratorefractive surgery.

Key Points: 
  • “We are pleased to begin enrollment in the LYNX-2 study of PS,” said George Magrath, M.D., M.B.A., M.S., CEO of Ocuphire.
  • Patients experience decreased low contrast visual acuity as well as glare, halos and starbursts.
  • There are currently no FDA-approved treatments for visual disturbances under low light conditions.
  • LYNX-2 is a randomized, double-masked, placebo-controlled Phase 3 registration study designed to evaluate the safety and efficacy of PS compared to placebo in subjects who underwent keratorefractive surgery and then reported decreased visual acuity under low light conditions.

Viatris Appoints Corinne Le Goff as Chief Commercial Officer

Retrieved on: 
Monday, April 15, 2024
Corinne, Business administration, Viatris, Paris Descartes University, Senior, Patient, Pharming, Health, Biotechnology, COVID-19, Growth, Amgen, Management

PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today.

Key Points: 
  • PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today.
  • Prior to joining Viatris, Le Goff was President and Chief Executive Officer of Imunon, a clinical-stage biotechnology company, where she led an organizational turnaround and rebranding effort.
  • Prior to Imunon, Le Goff served as Chief Commercial Officer at Moderna, where she was responsible for building the commercial organization and key capabilities necessary to ensure global access to Moderna's COVID-19 vaccine.
  • Le Goff said: "I am thrilled to join Viatris as the company embarks on its next exciting chapter.

Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

Retrieved on: 
Monday, April 1, 2024
Viatris, Patient, OCUP

FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ: VTRS).

Key Points: 
  • FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ: VTRS).
  • Ocuphire has a global license agreement with Viatris to co-develop and commercialize Phentolamine Ophthalmic Solution 0.75%.
  • Under the terms of this agreement, Ocuphire is eligible to receive regulatory and commercial milestones as well as royalties.

Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris

Retrieved on: 
Monday, March 11, 2024
Class Action Lawsuit, Professional Services, Legal, Claim, Agreement, Prejudice, Action, Defendant, Summons, Person, Viatris, CLASS, ARE, Settlement, Court of Common Pleas, Pfizer, Court, Hearing, Law, Generic drug

YOUR RIGHTS MAY BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.

Key Points: 
  • YOUR RIGHTS MAY BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.
  • A hearing will be held on June 12, 2024 at 1:00 p.m. Eastern Time, before the Hon.
  • Please do not contact the Court, the Clerk’s office, Viatris, the other Defendants, or their counsel regarding this notice.
  • All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to Lead Counsel or the Claims Administrator.

Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States

Retrieved on: 
Monday, April 1, 2024
Glaucoma, Agonist, Rheumatoid arthritis, Phenylephrine, Diabetes, Inflammation, Patient, Ageing, American Optometric Association, Eye injury, American Academy, Mydriasis, United, Viatris, Eye, Parasympatholytic, Uveitis, Lens, Pupil, Tropicamide, FDA, Cataract, Diabetic retinopathy, Food, Pharmaceutical industry

PITTSBURGH, April 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the United States.

Key Points: 
  • PITTSBURGH, April 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the United States.
  • The onset of action of RYZUMVI generally occurs in 30 minutes.
  • In the MIRA-2 trials' placebo group, 34% of patients were still dilated (had not returned to ≤ 0.2 mm of baseline pupil diameter) at 24 hours.
  • To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.

Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris

Retrieved on: 
Monday, March 11, 2024
Claim, Agreement, Prejudice, Action, Defendant, Summons, Person, Fee, Clerk, Viatris, ARE, Settlement, Counsel, Court of Common Pleas, Pfizer, Court, Hearing, Law, Generic drug

your rights MAY be affected by a class action lawsuit pending in this court.

Key Points: 
  • your rights MAY be affected by a class action lawsuit pending in this court.
  • A hearing will be held on June 12, 2024 at 1:00 p.m. Eastern Time, before the Hon.
  • Please do not contact the Court, the Clerk's office, Viatris, the other Defendants, or their counsel regarding this notice.
  • All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to Lead Counsel or the Claims Administrator.

Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions

Retrieved on: 
Thursday, January 4, 2024
Presbyopia, SPA, Pupil, Ciliary muscle, Food, FDA, GLARE, Night vision, Protocol, OCUP, Phentolamine, Patient, Safety, Viatris, Pharmaceutical industry

“The SPA agreement with the FDA provides a clear regulatory path for phentolamine ophthalmic solution in patients with poor night vision after keratorefractive surgery,” said George Magrath, M.D., M.B.A, M.S, CEO of Ocuphire.

Key Points: 
  • “The SPA agreement with the FDA provides a clear regulatory path for phentolamine ophthalmic solution in patients with poor night vision after keratorefractive surgery,” said George Magrath, M.D., M.B.A, M.S, CEO of Ocuphire.
  • LYNX-2 will be a multi-center, randomized, double-masked, placebo-controlled Phase 3 trial designed to evaluate the safety and efficacy of phentolamine ophthalmic solution in up to 200 patients in the U.S.
  • Under the terms of the November 2022 license agreement, Viatris will fund the development of phentolamine ophthalmic solution for the treatment of decreased visual acuity under dim (mesopic) light conditions and presbyopia.
  • Ocuphire is eligible to receive a milestone payment upon FDA approvals in these indications.

Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, December 21, 2023
PST, Conference, Viatris, Interest

PITTSBURGH, Dec. 21, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024.

Key Points: 
  • PITTSBURGH, Dec. 21, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024.
  • Chief Executive Officer Scott A. Smith , President Rajiv Malik and Chief Financial Officer Sanjeev Narula will represent the company in a presentation followed by a fireside chat scheduled at 10:30 a.m. PST / 1:30 p.m.
  • Interested parties can access a live webcast of the event at investor.viatris.com .
  • An archived version also will be available following the live event and can be accessed at the same location for a limited time.

Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Eye, Food and Drug Administration, Research, Food, Security (finance), Woman, End-user license agreement, American Academy, Patient, Phenylephrine, Presbyopia, FDA, Agonist, Tropicamide, License, Conference, Night vision, OCUP, Met, SPA, Mydriasis, Congress, Diabetic retinopathy, LPC, Pharmaceutical industry, Medical imaging, Cryptocurrency, Viatris, Ophthalmology

FARMINGTON HILLS, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Named as CEO; Conference Call Scheduled for December 5th, 2023, at 10 AM ET
    FARMINGTON HILLS, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • On August 10, 2023, Ocuphire entered into a common share purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”).
  • Third Quarter ended September 30, 2023, Financial Highlights
    As of September 30, 2023, Ocuphire had cash and cash equivalents of approximately $42.4 million.
  • For further details on Ocuphire’s financial results, refer to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, to be filed with the Securities and Exchange Commission.